APA (7th ed.) Citation

X, R., H, C., L, D., L, C., D, L., W, Y., . . . X, M. (2024). PIK3CA mutation-driven immune signature as a prognostic marker for evaluating the tumor immune microenvironment and therapeutic response in breast cancer. Journal of cancer research and clinical oncology, 150(3), 119. https://doi.org/10.1007/s00432-024-05626-4

Chicago Style (17th ed.) Citation

X, Ren, Cui H, Dai L, Chang L, Liu D, Yan W, Zhao X, Kang H, and Ma X. "PIK3CA Mutation-driven Immune Signature as a Prognostic Marker for Evaluating the Tumor Immune Microenvironment and Therapeutic Response in Breast Cancer." Journal of Cancer Research and Clinical Oncology 150, no. 3 (2024): 119. https://doi.org/10.1007/s00432-024-05626-4.

MLA (9th ed.) Citation

X, Ren, et al. "PIK3CA Mutation-driven Immune Signature as a Prognostic Marker for Evaluating the Tumor Immune Microenvironment and Therapeutic Response in Breast Cancer." Journal of Cancer Research and Clinical Oncology, vol. 150, no. 3, 2024, p. 119, https://doi.org/10.1007/s00432-024-05626-4.